Novartis, Otsuka, Pfizer, and Sanofi have all entered alliances with Verily, an Alphabet company, to support Project Baseline through its evidence generation platform.
Verily will use its baseline platform in its collaborations to bolster patient and clinician engagement in clinical trials and collect data in both the clinic and outside of it.
Novartis, Otsuka, Pfizer, and Sanofi will each launch clinical studies across varied therapeutic areas using Verily’s platform. The areas of research will include, cardiovascular disease, oncology, mental health, dermatology, and diabetes.
In a statement, Jessica Megan, chief medical and scientific officer at Verily, said that the four companies that have each partnered with Verily were early adopters of technology and digital tools to improve clinical research.
Created in 2017, the project was launched to develop technology and innovations to create a ‘precise map’ of human health. Verily has collaborated with a number of researchers, study sponsors, and volunteers since the initiation of Project Baseline including Duke University School of Medicine, Stanford Medicine, Google, and the American Heart Association.
A spokesperson for Verily told us: “We saw an opportunity to bring together a coalition of diverse stakeholders and build a platform that would collect, organize and activate comprehensive health information. Patients have always been our partners in this mission.”
Through the alliances, Verily and its partners will work to collect data from electronic health records (EHRs), sensors, and other digital sources, and organize the data through the baseline platform.
“In clinical trials or care, our understanding of a patient's health comes largely from limited interactions in a study site or clinic - but, in reality, so much of our experience with health occurs at home, remotely, and throughout our everyday lives. With emerging technology such as sensors, we believe it is possible to capture a more real-time, real-world understanding of a patient's health that can be used to inform better evidence and endpoints,” the spokesperson said.
